NextGen Scientific Corrects Details of $10 Million Capital Raise for Oncology and Dermatology Investments

NextGen Scientific LLC has issued an updated announcement to correct inaccurate information in a previous press release regarding the structure and use of proceeds from its current capital raise. The company is raising $10 million from accredited investors in a Regulation D, Rule 506(c) private placement offering.

Proceeds from the offering will be used to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, which include Genzada Pharmaceuticals USA and Hyatt Life Sciences. This strategic investment aims to build a diversified healthcare platform combining clinical innovation with active revenue streams.

Genzada Pharmaceuticals USA is an early-stage biotechnology company focused on oncology drug development. It has two clinical-stage drug candidates: GZ17-6.02, an oral compound being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University, and GZ21T, a topical therapy for cancerous and precancerous skin conditions expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands.

Capital raised will primarily support clinical and preclinical programs for these drug candidates, along with related drug manufacturing and development activities. ‘During our Phase I dose escalation study for GZ17-6.02, we observed promising biological effect against a broad array of cancer types and we are excited to further explore how this translates into meaningful clinical impact,’ said the company’s Chief Operating Officer Cameron West, MD, FAAD.

Hyatt Life Sciences represents the revenue-generating component of the investment, operating as a nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements. The company integrates traditional botanical knowledge with modern scientific validation within the rapidly expanding global nutraceuticals market.

Investors in the offering gain exposure to both clinical-stage drug development and a growing, revenue-generating supplements business. Proceeds will support clinical studies of GZ21T in atopic dermatitis, pre-clinical advancement, and the clinical and pre-clinical development of GZ17-6.02 for prostate and breast cancer, along with drug manufacturing activities and targeted marketing initiatives for the supplement portfolio. More information about the offering is available at https://investinnextgen.com/.

The company has included standard forward-looking statements and regulatory disclaimers with the announcement, noting that any offering will be made solely through official offering documents. The complete disclaimer information can be found at https://investinnextgen.com/disclaimers/.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NextGen Scientific Corrects Details of $10 Million Capital Raise for Oncology and Dermatology Investments.

The post NextGen Scientific Corrects Details of $10 Million Capital Raise for Oncology and Dermatology Investments appeared first on citybuzz.